The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“p53 negatively affects the expression of PTEN and Parkin, which are regulators of the PI3K/AKT signaling pathway and suppress glycolysis.89,90”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598
Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881
Presenilin-Dependent -Secretase-Mediated Control of p53-Associated Cell Death in Alzheimer's Disease
Alves da Costa, C., Sunyach, C., Pardossi-Piquard, R., Sevalle, J., Vincent, B., Boyer, N., Kawarai, T., Girardot, N., St. George-Hyslop, P., & Checler, F. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.0651-06.2006 · Cited by 168
Self-citation
Research works printed but not linked: 47
- Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007; 21: 2683–2710. · DOI · Paper page
- Bourdon JC, De Laurenzi V, Melino G, Lane DP . p53: 25 years of recherche and more questions to answer. Cell Death Differ 2003; 10: 397–399. · DOI
- Lane DP . Cancer. p53, guardian of the genome. Nature 1992; 358: 15–16. · DOI · Paper page
- Lim YP, Lim TT, Chan YL, Song AC, Yeo BH, Vojtesek B et al. The p53 knowledgebase: an integrated information resource for p53 research. Oncogene 2007; 26: 1517–1521. · DOI
- Asker C, Wiman KG, Selivanova G . p53-induced apoptosis as a safeguard against cancer. Biochem Biophys Res Commun 1999; 265: 1–6. · DOI
- Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P . p53 mutations in nonastrocytic human brain tumors. Cancer Res 1991; 51: 6202–6205.
- Nayak A, Ralte AM, Sharma MC, Singh VP, Mahapatra AK, Mehta VS et al. p53 protein alterations in adult astrocytic tumors and oligodendrogliomas. Neurol India 2004; 52: 228–232.
- Ohgaki H, Kleihues P . Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007; 170: 1445–1453. · DOI · Paper page
- Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997; 56: 1098–1104. · DOI · Paper page
- Deguin-Chambon V, Vacher M, Jullien M, May E, Bourdon JC . Direct transactivation of c-Ha-Ras gene by p53: evidence for its involvement in p53 transactivation activity and p53-mediated apoptosis. Oncogene 2000; 19: 5831–5841. · DOI
- Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, McAdams H et al. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci USA 2003; 100: 5956–5961. · DOI · Paper page
- Letessier A, Garrido-Urbani S, Ginestier C, Fournier G, Esterni B, Monville F et al. Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer. Oncogene 2007; 26: 298–307. · DOI
- Poulogiannis G, McIntyre RE, Dimitriadi M, Apps JR, Wilson CH, Ichimura K et al. PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci USA 2010; 107: 15145–15150. · DOI · Paper page
- Fujiwara M, Marusawa H, Wang HQ, Iwai A, Ikeuchi K, Imai Y et al. Parkin as a tumor suppressor gene for hepatocellular carcinoma. Oncogene 2008; 27: 6002–6011. · DOI · Paper page
- Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I et al. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet 2010; 42: 77–82. · DOI · Paper page
- da Costa CA, Sunyach C, Giaime E, West A, Corti O, Brice A et al. Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. Nat Cell Biol 2009; 11: 1370–1375. · DOI · Paper page
- Rotter V . p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells. Proc Natl Acad Sci USA 1983; 80: 2613–2617. · DOI
- Miyashita T, reed JC . Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293–299. · DOI · Paper page
- Miyashita T, Harigai M, Hanada M, Reed JC . Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994; 54: 3131–3135.
- Basu A, Haldar S . The relationship between BcI2, Bax and p53: consequences for cell cycle progression and cell death. Mol Hum Reprod 1998; 4: 1099–1109. · DOI · Paper page
- Hemann MT, Lowe SW . The p53-Bcl-2 connection. Cell Death Differ 2006; 13: 1256–1259. · DOI · Paper page
- Zinkel S, Gross A, Yang E . BCL2 family in DNA damage and cell cycle control. Cell Death Differ 2006; 13: 1351–1359. · DOI · Paper page
- Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799–1805.
- Watanabe K, Sato K, Biernat W, Tachibana O, von Ammon K, Ogata N et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 1997; 3: 523–530.
- Nozaki M, Tada M, Kobayashi H, Zhang CL, Sawamura Y, Abe H et al. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. Neuro Oncol 1999; 1: 124–137. · DOI
- Wang F, Denison S, Lai JP, Philips LA, Montoya D, Kock N et al. Parkin gene alterations in hepatocellular carcinoma. Genes Chromosomes Cancer 2004; 40: 85–96. · DOI
- Henn IH, Gostner JM, Lackner P, Tatzelt J, Winklhofer KF . Pathogenic mutations inactivate parkin by distinct mechanisms. J Neurochem 2005; 92: 114–122. · DOI
- Soussi T, Hamroun D, Hjortsberg L, Rubio-Nevado JM, Fournier JL, Beroud C . MUT-TP53 2.0: a novel versatile matrix for statistical analysis of TP53 mutations in human cancer. Hum Mutat 2010; 31: 1020–1025. · DOI
- Edlund K, Larsson O, Ameur A, Bunikis I, Gyllensten U, Leroy B et al. Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors. Proc Natl Acad Sci USA 2012; 109: 9551–9556. · DOI
- Costa SL, Paillaud E, Fages C, Rochette-Egly C, Plassat JL, Jouault H et al. Effects of a novel synthetic retinoid on malignant glioma in vitro: inhibition of cell proliferation, induction of apoptosis and differentiation. Eur J Cancer 2001; 37: 520–530. · DOI
- Hainaut P, Soussi T, Shomer B, Hollstein M, Greenblatt M, Hovig E et al. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res 1997; 25: 151–157. · DOI · Paper page
- Ginsberg D, Oren M, Yaniv M, Piette J . Protein-binding elements in the promoter region of the mouse p53 gene. Oncogene 1990; 5: 1285–1290.
- Zhang C, Lin M, Wu R, Wang X, Yang B, Levine AJ et al. Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proc Natl Acad Sci USA 2011; 108: 16259–16264. · DOI · Paper page
- Picchio MC, Martin ES, Cesari R, Calin GA, Yendamuri S, Kuroki T et al. Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer. Clin Cancer Res 2004; 10: 2720–2724. · DOI
- Agirre X, Roman-Gomez J, Vazquez I, Jimenez-Velasco A, Garate L, Montiel-Duarte C et al. Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia. Int J Cancer 2006; 118: 1945–1953. · DOI
- Fulci G, Ishii N, Van Meir EG . p53 and brain tumors: from gene mutations to gene therapy. Brain Pathol 1998; 8: 599–613. · DOI
- Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H . Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996; 6: 217–223 discussion 23-4. · DOI · Paper page
- Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009; 27: 5743–5750. · DOI · Paper page
- Sigal A, Rotter V . Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000; 60: 6788–6793.
- Haupt Y, Maya R, Kazaz A, Oren M . Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296–299. · DOI · Paper page
- Midgley CA, Lane DP . p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 1997; 15: 1179–1189. · DOI · Paper page
- Hollstein M, Sidransky D, Vogelstein B, Harris CC . p53 mutations in human cancers. Science 1991; 253: 49–53. · DOI · Paper page
- Yeo CW, Ng FS, Chai C, Tan JM, Koh GR, Chong YK et al. Parkin pathway activation mitigates glioma cell proliferation and predicts patient survival. Cancer Res 2012; 72: 2543–2553. · DOI
- Pardossi-Piquard R, Petit A, Kawarai T, Sunyach C, Alves da costa C, Vincent B et al. Presenilin-dependent transcriptional control of the Aβ-degrading enzyme neprilysin by intracellular domains of β APP and APLP. Neuron 2005; 46: 541–554. · DOI · Paper page
- West AB, Lockhart PJ, O'Farell C, Farrer MJ . Identification of a novel gene linked to parkin via a bi-directional promoter. J Mol Biol 2003; 326: 11–19. · DOI
- Idbaih A, Marie Y, Pierron G, Brennetot C, Hoang-Xuan K, Kujas M et al. Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol 2005; 58: 483–487. · DOI · Paper page
- Idbaih A, Marie Y, Lucchesi C, Pierron G, Manie E, Raynal V et al. BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer 2008; 122: 1778–1786. · DOI
Cited by
The pharmacological regulation of cellular mitophagy
Georgakopoulos, N. D., Wells, G., & Campanella, M. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2287 · Cited by 319
Challenges in glioblastoma research: focus on the tumor microenvironment
Bikfalvi, A., da Costa, C. A., Avril, T., Barnier, J.-V., Bauchet, L., Brisson, L., Cartron, P. F., Castel, H., Chevet, E., Chneiweiss, H., et al. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2022.09.005 · Cited by 302
Self-citationTumor suppressor p53 and metabolism
Liu, J., Zhang, C., Hu, W., & Feng, Z. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy070 · Cited by 300
Parkin and mitophagy in cancer
Bernardini, J. P., Lazarou, M., & Dewson, G. (2017) · Oncogene · doi:10.1038/onc.2016.302 · Cited by 281
Inhibition of apoptotic Bax translocation to the mitochondria is a central function of parkin
Charan, R. A., Johnson, B. N., Zaganelli, S., Nardozzi, J. D., & LaVoie, M. J. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.278 · Cited by 67
Metadata
- Authors
- Viotti, J., Duplan, E., Caillava, C., Condat, J., Goiran, T., Giordano, C., Marie, Y., Idbaih, A., Delattre, J.-Y., Honnorat, J., Checler, F., & Alves da Costa, C.
- Venue
- Oncogene
- Published
- 2013-05-06
- Volume
- 33
- Issue
- 14
- Pages
- 1764-1775
- ISSN
- 0950-9232
- 1476-5594
- Cited by
- 65
- References
- 6
- Language
- en
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity. https://app.cochat.ai/papers/10.1038/onc.2013.124
- The paper
- Viotti, J., Duplan, E., Caillava, C., Condat, J., Goiran, T., Giordano, C., Marie, Y., Idbaih, A., Delattre, J.-Y., Honnorat, J., Checler, F., & Alves da Costa, C. (2014). Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity. Oncogene. https://doi.org/10.1038/onc.2013.124
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.